Edition:
United States

Pieris Pharmaceuticals Inc (PIRS.OQ)

PIRS.OQ on NASDAQ Stock Exchange Capital Market

5.06USD
18 Jun 2018
Change (% chg)

$-0.11 (-2.13%)
Prev Close
$5.17
Open
$5.18
Day's High
$5.24
Day's Low
$5.06
Volume
23,164
Avg. Vol
180,044
52-wk High
$9.69
52-wk Low
$4.27

Latest Key Developments (Source: Significant Developments)

Pieris Pharmaceuticals Prices Public Offering Of 5.50 Mln Common Shares At $8/Share
Wednesday, 14 Feb 2018 12:27am EST 

Feb 14 (Reuters) - Pieris Pharmaceuticals Inc ::PIERIS PHARMACEUTICALS ANNOUNCES PRICING OF ITS PUBLIC OFFERING.SAYS PUBLIC OFFERING OF 5.50 MILLION COMMON SHARES PRICED AT $8.00PER SHARE.  Full Article

Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration
Friday, 9 Feb 2018 06:45am EST 

Feb 9 (Reuters) - Pieris Pharmaceuticals Inc ::SEATTLE GENETICS AND PIERIS PHARMACEUTICALS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION.SEATTLE GENETICS INC - ‍SEATTLE GENETICS WILL PAY PIERIS A $30 MILLION UPFRONT FEE, TIERED ROYALTIES ON NET SALES UP TO LOW DOUBLE-DIGITS​.SEATTLE GENETICS - CO, PIERIS TO EVALUATE BISPECIFIC IMMUNO-ONCOLOGY AGENTS COMBINING PIERIS' ANTICALIN TECHNOLOGY WITH SOME OF CO'S CANCER-TARGETED ANTIBODIES.SEATTLE GENETICS - UNDER TERMS OF AGREEMENT CO TO PAY PIERIS UP TO $1.2 BILLION IN TOTAL SUCCESS-BASED PAYMENTS ACROSS THREE PRODUCT CANDIDATES.SEATTLE GENETICS INC - ‍SEATTLE GENETICS WILL SOLELY DEVELOP, FUND AND COMMERCIALIZE OTHER TWO PROGRAMS​.SEATTLE GENETICS-PIERIS PHARMA, CO HAVE ENTERED INTO AGREEMENT FOR DEVELOPING MULTIPLE TARGETED BISPECIFIC IMMUNO-ONCOLOGY TREATMENTS FOR BLOOD CANCERS.SEATTLE GENETICS INC - ‍PRIOR TO INITIATION OF A PIVOTAL TRIAL, PIERIS MAY OPT INTO GLOBAL CO-DEVELOPMENT AND U.S. COMMERCIALIZATION OF SECOND PROGRAM​.SEATTLE GENETICS - PRIOR TO INITIATION OF PIVOTAL TRIAL, PIERIS MAY OPT FOR A SHARE IN GLOBAL COSTS, PROFITS ON 50/50 BASIS FOR SECOND PROGRAM.  Full Article

Pieris Pharma Doses First Subjects In Phase I Study Of PRS-060
Wednesday, 20 Dec 2017 08:03am EST 

Dec 20 (Reuters) - Astrazeneca Plc ::PIERIS PHARMACEUTICALS-DOSED FIRST SUBJECTS IN PHASE I STUDY OF PRS-060, TRIGGERING $12.5 MILLION MILESTONE PAYMENT FROM ASTRAZENECA TO CO-SEC FILING.  Full Article

Pieris Pharma Received Clearance to Initiate Its First-In-Human Study In Australia For PRS-060/AZD1402
Thursday, 7 Dec 2017 08:30am EST 

Dec 7 (Reuters) - Pieris Pharmaceuticals Inc ::PIERIS PHARMACEUTICALS - RECEIVED ETHICS AND REGULATORY CLEARANCE TO INITIATE ITS FIRST-IN-HUMAN STUDY IN AUSTRALIA FOR PRS-060/AZD1402.PIERIS PHARMACEUTICAL - THE PHASE 1 STUDY IS BEING DEVELOPED AS PART OF PIERIS' STRATEGIC ALLIANCE WITH ASTRAZENECA.PIERIS PHARMACEUTICALS - DOSING FIRST SUBJECT IN TRIAL FOR PRS-060/AZD1402 BY YEAR END.  Full Article

Pieris Pharmaceuticals appoints James Geraghty as chairman of board of directors
Tuesday, 21 Nov 2017 08:30am EST 

Nov 21 (Reuters) - Pieris Pharmaceuticals Inc :Pieris Pharmaceuticals appoints James Geraghty as chairman of the board of directors.Pieris Pharmaceuticals Inc - ‍Geraghty replaces Chau Khuong, who is stepping down from board​.  Full Article

Pieris Pharmaceuticals reports Q3 loss per share $0.16
Wednesday, 8 Nov 2017 04:30pm EST 

Nov 8 (Reuters) - Pieris Pharmaceuticals Inc :Pieris Pharmaceuticals reports financial results for the third quarter ended september 30, 2017, and provides corporate update.Q3 loss per share $0.16.Pieris Pharmaceuticals Inc - ‍cash and equivalents totaled $89.9 million as of September 30, 2017, compared to $29.4 million as of December 31, 2016​.  Full Article

Sichuan Kelun Pharmaceutical unit signs license agreement with Pieris Pharmaceuticals
Thursday, 10 Aug 2017 06:48am EDT 

Aug 10(Reuters) - Sichuan Kelun Pharmaceutical Co Ltd <002422.SZ>:Says its Sichuan-based unit signs license agreement with Pieris Pharmaceuticals Inc <<>>, regarding a patent of tumour immunotherapy .Says the unit grants Pieris Pharmaceuticals to use the license to develop and produce related products.Says Pieris Pharmaceuticals needs to pay milestone payments up to $94 million to the unit in development and sales and to pay sales commissions to the unit .  Full Article

Pieris Pharmaceuticals Q2 loss per share $0.23
Wednesday, 9 Aug 2017 05:20pm EDT 

Aug 9 (Reuters) - Pieris Pharmaceuticals Inc :Pieris Pharmaceuticals reports financial results for the second quarter ended June 30, 2017 and provides corporate update.Q2 loss per share $0.23.Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.  Full Article

T2 Biosystems names Darlene Deptula-Hicks as CFO
Monday, 1 May 2017 09:00am EDT 

May 1 (Reuters) - T2 Biosystems Inc : :T2 Biosystems names Darlene Deptula-Hicks as chief financial officer.Deptula-Hicks was most recently CFO and senior vice president at Pieris Pharmaceuticals Inc.T2 Biosystems Inc - Deptula-Hicks was most recently CFO and senior vice president at Pieris Pharmaceuticals Inc.  Full Article

Pieris signs partnership for anemia drug PRS-080, granting exclusive option in Japan to Aska pharmaceutical
Monday, 27 Feb 2017 07:30am EST 

Pieris Pharmaceuticals Inc : Pieris signs partnership for anemia drug PRS-080, granting exclusive option in Japan to Aska Pharmaceutical . Pieris Pharmaceuticals Inc - co will receive an immediate option payment of $2.75 million usd from Aska . Pieris Pharmaceuticals Inc - a Phase 1 study conducted in healthy volunteers demonstrated that a single dose of PRS-080 was well tolerated . Pieris Pharmaceuticals Inc - Pieris may also receive double-digit royalties on net sales of PRS-080 up to mid- to high-teens . Pieris Pharmaceuticals Inc - PRS-060, anticipated to begin a first-in-human study around middle of 2017 . Pieris Pharmaceuticals Inc - PRS-343 scheduled to enter a first-in patient trial in first half of 2017 .Pieris Pharmaceuticals - should Aska exercise option, Pieris would be eligible for over $80 million usd in combined option exercise fee and milestones.  Full Article

BRIEF-Pieris Pharmaceuticals Reports Q1 Loss Per Share $0.17

* PIERIS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE